LRMR Larimar Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1374690 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-18.2%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-129.8%
ROA-95.2%
ROIC (approx.)-348.7%
Asset turnover—
Leverage & solvency
Liabilities / assets27.8%
Debt / equity0.00x
Current ratio3.82x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio1.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $154.22M | $73.28M | $27.67M | $24.25M | $38.40M |
| SG&A expense | $18.27M | $17.61M | $14.09M | $12.28M | $12.07M |
| Operating income | -$172.50M | -$90.89M | -$41.76M | -$36.53M | -$50.47M |
| Pretax income | -$165.67M | -$80.60M | -$36.95M | -$35.35M | -$50.64M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$165.67M | -$80.60M | -$36.95M | -$35.35M | -$50.64M |
| EBITDA | -$172.15M | -$90.57M | -$41.45M | -$36.21M | -$50.14M |
| EPS (basic) | — | -1.32 | -0.84 | -1.37 | -2.95 |
| EPS (diluted) | — | -1.32 | -0.84 | -1.37 | -2.95 |
| Weighted avg. shares (diluted) | — | 61.26M | 43.90M | 25.76M | 17.16M |
| Balance sheet | |||||
| Cash & equivalents | $85.41M | $33.22M | $26.75M | $26.82M | $70.10M |
| Short-term investments | $51.44M | $150.24M | $60.04M | $91.60M | — |
| Current assets | $142.02M | $195.30M | $90.17M | $120.74M | $72.20M |
| PP&E, net | $622,000 | $881,000 | $684,000 | $831,000 | $1.05M |
| Total assets | $145.84M | $200.22M | $95.94M | $126.41M | $78.67M |
| Current liabilities | $64.80M | $24.36M | $9.51M | $10.71M | $8.85M |
| Total liabilities | $67.76M | $28.41M | $14.21M | $15.50M | $14.25M |
| Shareholders' equity | $78.08M | $171.81M | $81.72M | $110.90M | $64.41M |
| Shares outstanding | 83.09M | 63.82M | 43.91M | 43.27M | 17.71M |
| Cash flow statement | |||||
| Operating cash flow | -$113.20M | -$70.76M | -$33.46M | -$27.57M | -$42.10M |
| Capital expenditure | $91,000 | $515,000 | $164,000 | $100,000 | $333,000 |
| Free cash flow | -$113.29M | -$71.28M | -$33.62M | -$27.67M | -$42.44M |
| Investing cash flow | $100.31M | -$85.39M | $33.35M | -$90.96M | $24.17M |
| Financing cash flow | $65.09M | $161.88M | $30,000 | $75.26M | $19.89M |
| Depreciation & amortization | $350,000 | $318,000 | $311,000 | $318,000 | $326,000 |
| Stock-based compensation | $7.00M | $8.80M | $7.62M | $6.62M | $5.47M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.